Assert-IQ vs ElucidVivo A.3

Loosely related. A direct comparison may be less useful — each tool solves a different problem. Comparability 20/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

ElucidVivo A.3

by Elucid

AI Verdict

These tools are not directly comparable as they address different aspects of cardiovascular health. Assert-IQ is an insertable cardiac monitor focused on detecting and managing heart rhythm disorders through continuous ECG monitoring. ElucidVivo A.3, on the other hand, is an AI-powered image analysis system that quantifies arterial plaque composition from CT angiography to aid in atherosclerosis management.

Choose Assert-IQ if…

Choose Assert-IQ if your primary need is long-term, continuous monitoring for patients with suspected heart rhythm disorders. This tool is ideal for detecting infrequent or asymptomatic arrhythmias over several years, providing comprehensive data for diagnosis and ongoing management through remote monitoring and proactive alerts.

View Assert-IQ →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography. This system is best suited for stratifying atherosclerosis patients and optimizing treatment decisions by providing detailed visualization and objective measurements of plaque characteristics, including lipid-rich necrotic core and calcifications.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	ElucidVivo A.3
Deployment	Subcutaneously implanted device with mobile app connectivity	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Assert-IQ

Assert-IQ prioritizes usability for both patients and clinicians through its minimally invasive insertion, patient activator for symptom logging, and remote monitoring capabilities via a secure cloud platform and mobile app. This simplifies the long-term cardiac monitoring process for all stakeholders. While ElucidVivo A.3 offers advanced visualization for specialists, Assert-IQ's broader patient-centric and remote workflow benefits give it an edge in overall usability.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 offers a highly detailed, quantitative, and histology-validated analysis of arterial plaque composition and stability from CT angiography, including the derivation of fractional flow reserve (FFRct). This provides a more granular and evidence-backed diagnostic capability for atherosclerosis patient stratification and treatment optimization. Assert-IQ provides valuable long-term arrhythmia monitoring, but ElucidVivo A.3's advanced, validated diagnostic insights represent a deeper clinical impact in its specialized domain.

Pricing & Value

Tie

Both Assert-IQ and ElucidVivo A.3 employ opaque pricing models, requiring direct contact for institutional or enterprise pricing, and neither explicitly offers a free trial. Without specific pricing details or publicly available cost-benefit analyses, it is not possible to definitively compare their value propositions. Therefore, they are a tie in this dimension.

Enterprise Readiness

Assert-IQ

Assert-IQ benefits from being a product of Abbott Medical, a large and established healthcare company, which inherently suggests robust enterprise-level support, explicit HIPAA compliance, FDA clearance, and a proven track record for large-scale deployments. While ElucidVivo A.3 also has FDA clearance and integrates with PACS/EMR, the explicit compliance statements and backing of a major corporation give Assert-IQ a stronger position in enterprise readiness.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates a higher degree of innovation by leveraging AI for a novel, quantitative, and histology-validated analysis of arterial plaque composition and stability from CT images, including the derivation of FFRct. This pushes the boundaries of non-invasive diagnostic imaging for atherosclerosis more significantly. Assert-IQ's advancements in ICM technology, while valuable, primarily enhance existing monitoring concepts with extended duration and connectivity.

Support & Docs

Assert-IQ

Abbott Medical provides comprehensive support and documentation for Assert-IQ, including detailed clinician and patient manuals, technical support contact information, and online resources. In contrast, specific details regarding the level of support or documentation for ElucidVivo A.3 are not readily available in the provided facts or web search results, making Assert-IQ the clear winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	ElucidVivo A.3
Name	Assert-IQ	ElucidVivo A.3
Company	Abbott Medical	Elucid Bioimaging
Primary Use Case	Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.	AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
Primary Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Radiology & Imaging AI
Target Medical Specialties	Cardiology, Internal Medicine	Cardiology, Radiology, Vascular Surgery
Example Key Feature	Long-term continuous cardiac monitoring (up to 6 years)	AI-powered quantitative analysis of arterial plaque

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of Assert-IQ and ElucidVivo A.3, and how do they differ in addressing cardiovascular conditions?

Assert-IQ is an insertable cardiac monitor system designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. ElucidVivo A.3 is an AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting in atherosclerosis patient stratification and optimizing treatment decisions.

What type of patient data or imaging is required for each system to generate its insights?

Assert-IQ requires data from a subcutaneously inserted cardiac monitor that continuously monitors heart rhythms. ElucidVivo A.3 requires CT angiography images to perform its AI-powered quantitative analysis of arterial plaque.

What specific diagnostic insights or measurements do these tools provide to assist in patient management?

Assert-IQ provides advanced arrhythmia detection algorithms, remote monitoring capabilities, and proactive clinician alerts based on continuous cardiac rhythm data, including detection of PVCs and postural changes. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, visualizes lesion-level plaque composition in 3D, and derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.

For which patient populations is each tool primarily intended?

Assert-IQ is intended for patients with suspected heart rhythm disorders, including those with unexplained symptoms like dizziness, palpitations, chest pain, syncope, shortness of breath, or those at risk for cardiac arrhythmias such as bradycardia, tachycardia, sinus pauses, or atrial fibrillation. ElucidVivo A.3 is designed to aid physicians in stratifying patients with atherosclerosis by offering detailed visualization and measurement of plaque characteristics.

How do Assert-IQ and ElucidVivo A.3 integrate into existing clinical workflows and IT infrastructure?

Assert-IQ utilizes a hybrid deployment with a secure cloud-based data platform and remote monitoring capabilities, allowing for remote programming and data transmission via Bluetooth to a patient's mobile device or a separate transmitter. ElucidVivo A.3 is a software application, likely on-premise or cloud-based, that integrates with PACS/EMR systems for medical image analysis.

What is the duration or scope of monitoring or analysis provided by each system?

Assert-IQ provides long-term continuous cardiac monitoring for up to six years, with options for three or six-year battery life. ElucidVivo A.3 performs a detailed, quantitative analysis of arterial plaque from CT angiography images, offering a snapshot of plaque characteristics at the time of the scan.